GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Retained Earnings

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Retained Earnings : $-56.11 Mil (As of Dec. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Parnell Pharmaceuticals Holdings's retained earnings for the quarter that ended in Dec. 2018 was $-56.11 Mil.

Parnell Pharmaceuticals Holdings's quarterly retained earnings declined from Dec. 2016 ($-40.61 Mil) to Dec. 2017 ($-59.94 Mil) but then increased from Dec. 2017 ($-59.94 Mil) to Dec. 2018 ($-56.11 Mil).

Parnell Pharmaceuticals Holdings's annual retained earnings declined from Dec. 2016 ($-40.61 Mil) to Dec. 2017 ($-59.94 Mil) but then increased from Dec. 2017 ($-59.94 Mil) to Dec. 2018 ($-56.11 Mil).


Parnell Pharmaceuticals Holdings Retained Earnings Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Retained Earnings Chart

Parnell Pharmaceuticals Holdings Annual Data
Trend Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Retained Earnings
Get a 7-Day Free Trial -17.24 -24.34 -40.61 -59.94 -56.11

Parnell Pharmaceuticals Holdings Semi-Annual Data
Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Retained Earnings Get a 7-Day Free Trial -17.24 -24.34 -40.61 -59.94 -56.11

Parnell Pharmaceuticals Holdings Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Parnell Pharmaceuticals Holdings  (OTCPK:PARNF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
N/A
Address
476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015
Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.